SRZN

SEC source: 0001593968-25-000608 · primary_01.xml · derivative · entry 1

WOODHOUSE DAVID J · CIK 0001642995 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-25-000612 · primary_01.xml · derivative · entry 1

CHAI CHRISTOPHER Y · CIK 0001413823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-25-000613 · primary_01.xml · derivative · entry 1

BJERKHOLT ERIC · CIK 0001197350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-25-000609 · primary_01.xml · derivative · entry 1

Lin Shao-Lee · CIK 0001725092 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-25-000611 · primary_01.xml · derivative · entry 1

Haak-Frendscho Mary · CIK 0001873902 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-25-000610 · primary_01.xml · derivative · entry 1

Rothenberg Mace · CIK 0001873988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2035-05-14

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-25-000592 · primary_01.xml · derivative · entry 2

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,750

Underlying: Common Stock · 33,750 shares

Expires 2035-05-01

F3 · derivative.exercise_date: The shares subject to the option award vest over a four-year period in 48 equal monthly installments measured from grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001593968-25-000592 · primary_01.xml · derivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The shares subject to the RSU award vest over a two-year period as to 50% of such shares on each of the first and second annual anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The shares subject to the RSU award vest over a two-year period as to 50% of such shares on each of the first and second annual anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001593968-25-000591 · primary_01.xml · derivative · entry 2

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The shares subject to the RSU award vest over a two-year period as to 50% of such shares on each of the first and second annual anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

F3 · derivative.expiration_date: The shares subject to the RSU award vest over a two-year period as to 50% of such shares on each of the first and second annual anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001593968-25-000591 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2035-05-01

F1 · derivative.exercise_date: The shares subject to the option award vest over a four-year period in 48 equal monthly installments measured from grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001593968-25-000593 · primary_01.xml · derivative · entry 2

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,750

Underlying: Common Stock · 8,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The shares subject to the RSU award vest over a two-year period as to 50% of such shares on each of the first and second annual anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

F3 · derivative.expiration_date: The shares subject to the RSU award vest over a two-year period as to 50% of such shares on each of the first and second annual anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001593968-25-000593 · primary_01.xml · derivative · entry 1

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Common Stock · 26,250 shares

Expires 2035-05-01

F1 · derivative.exercise_date: The shares subject to the option award vest over a four-year period in 48 equal monthly installments measured from grant date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 21

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group Opportunity II, LP

Disclosed balance after: 517,241

Underlying: Common Stock · 775,861 shares

Expires not disclosed

F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F15 · derivative.underlying_shares: Consists of (a) 517,241 shares of the Issuer's Common Stock and (b) 258,620 Series E Warrants to purchase shares of the Issuer's Common Stock.

F5 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 20

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 548,653

Underlying: Common Stock · 822,980 shares

Expires not disclosed

F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F14 · derivative.underlying_shares: Consists of (a) 548,653 shares of the Issuer's Common Stock and (b) 274,327 Series E Warrants to purchase shares of the Issuer's Common Stock.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 19

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 485,830

Underlying: Common Stock · 728,745 shares

Expires not disclosed

F11 · security: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · security: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · price: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · price: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · derivative.exercise_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · derivative.exercise_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F11 · derivative.expiration_date: Each Second Tranche Unit consists of (a) one share of the Issuer's Common Stock and (b) one half of a Series E Common Warrant to purchase shares of Common Stock. The Second Tranche Units may be purchased in a second closing (the "Second Closing"). The Second Closing is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Issuer's Investigation New Drug Application for SZN-8141 (the "Second Closing Milestone"); provided, that the Second Closing may not occur prior to six months and one day following March 26, 2025. If the Issuer terminates its SZN-8141 program prior to October 31, 2026, then the Issuer is required to provide written notice to each purchaser of Second Tranche Units no later than two trading days following such termination (the "Termination Notice").

F12 · derivative.expiration_date: (Continued from footnote 11) Each purchaser of Second Tranche Units will have the right, but not the obligation, for 30 calendar days following the receipt of the Termination Notice, upon written notice to the Issuer, to purchase the Second Tranche Units subscribed for by such purchaser in the Second Closing. In addition, at any time prior to October 31, 2026 or the date of the Termination Notice (if earlier), in lieu of the requirement to purchase Second Tranche Units in the Second Closing, each purchaser of Second Tranche Units has the right, but not the obligation, upon five trading days' prior written notice to the Issuer to purchase all (but not a portion) of the Second Tranche Units subscribed for by such purchaser in the Second Closing.

F13 · derivative.underlying_shares: Consists of (a) 485,830 shares of the Issuer's Common Stock and (b) 242,915 Series E Warrants to purchase shares of the Issuer's Common Stock.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 18

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group Opportunity II, LP

Disclosed balance after: 172,414

Underlying: Common Stock · 172,414 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement").

F10 · derivative.exercise_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations).

F10 · derivative.expiration_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations).

F5 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 17

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 182,884

Underlying: Common Stock · 182,884 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement").

F10 · derivative.exercise_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations).

F10 · derivative.expiration_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations).

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 16

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 161,943

Underlying: Common Stock · 161,943 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement").

F10 · derivative.exercise_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations).

F10 · derivative.expiration_date: These Series E Common Warrants are exercisable immediately and will not expire until exercised in full (subject to certain beneficial ownership limitations).

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 15

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 0

Underlying: Common Stock · 397,773 shares

Expires not disclosed

F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 14

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 0

Underlying: Common Stock · 352,225 shares

Expires not disclosed

F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 13

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 0

Underlying: Common Stock · 397,773 shares

Expires not disclosed

F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 12

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 0

Underlying: Common Stock · 352,225 shares

Expires not disclosed

F9 · kind: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F9 · price: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F9 · derivative.exercise_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F9 · derivative.expiration_date: These Series C Common Warrants and Series D Common Warrants were cancelled by the Issuer in connection with the 2025 Private Placement.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 11

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 111,656

Underlying: Common Stock · 111,656 shares

Expires not disclosed

F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 10

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 0

Underlying: Common Stock · 111,656 shares

Expires not disclosed

F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 9

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 98,870

Underlying: Common Stock · 98,870 shares

Expires not disclosed

F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 8

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 0

Underlying: Common Stock · 98,870 shares

Expires not disclosed

F7 · kind: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · kind: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · price: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · price: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.exercise_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.exercise_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F7 · derivative.expiration_date: These Series B Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series B Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule,

F8 · derivative.expiration_date: (Continued from footnote 7) and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 7

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 102,651

Underlying: Common Stock · 102,651 shares

Expires not disclosed

F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 6

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 0

Underlying: Common Stock · 102,651 shares

Expires not disclosed

F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 5

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 90,897

Underlying: Common Stock · 90,897 shares

Expires not disclosed

F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · derivative · entry 4

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 0

Underlying: Common Stock · 90,897 shares

Expires not disclosed

F6 · kind: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · price: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.exercise_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F6 · derivative.expiration_date: These Series A Common Warrants were initially purchased as part of a unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which TCG III LP and TCG III-A LP purchased in the Issuer's private placement on April 4, 2024. The exercise price of these Series A Common Warrants was reduced to $11.54 per share in connection with the 2025 Private Placement. These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · nonDerivative · entry 3

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group Opportunity III, LP

Disclosed balance after: 344,827

F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement").

F5 · ownership.nature: The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Members"). TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 795,411

F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement").

F2 · balance_after: The amount beneficially owned by the Reporting Persons, has been updated to correct an administrative error in previously reported Form 4s.

F4 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047104 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Column Group Opportunity III, LP · CIK 0001931825 · 10% owner

Column Group Opportunity III GP, LP · CIK 0001932874 · 10% owner

TCG Opportunity III GP, LLC · CIK 0001932445 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 704,332

F1 · price: Represents a price per unit, consisting of (i) $11.5375 per share of the Issuer's Common Stock and (ii) $0.0625 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP"), The Column Group III-A, LP ("TCG III-A LP") and The Column Group Opportunity III, LP ("TCG Opportunity III LP") purchased in the Issuer's private placement on March 24, 2025 (the "2025 Private Placement").

F2 · balance_after: The amount beneficially owned by the Reporting Persons, has been updated to correct an administrative error in previously reported Form 4s.

F3 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-25-047110 · ownership.xml · derivative · entry 1

Kutzkey Tim · CIK 0001614186 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,666

Underlying: Common Stock · 2,666 shares

Expires 2035-03-25

F1 · derivative.exercise_date: The options vest ratably over 36 months from the grant date, subject to the Reporting Person's continuous service as of each such date.

SEC source: 0001593968-25-000414 · primary_01.xml · derivative · entry 6

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,603

Underlying: Common Stock · 1,603 shares

Expires not disclosed

F2 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $15.71 to $12.45.

F3 · derivative.expiration_date: The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

SEC source: 0001593968-25-000414 · primary_01.xml · derivative · entry 5

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,474

Underlying: Common Stock · 1,474 shares

Expires 2029-04-04

F1 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $16.96 to $12.45.

SEC source: 0001593968-25-000414 · primary_01.xml · derivative · entry 4

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F4 · kind: The warrant was cancelled pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025.

F6 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

F6 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

SEC source: 0001593968-25-000414 · primary_01.xml · derivative · entry 3

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F4 · kind: The warrant was cancelled pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025.

F5 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

F5 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

SEC source: 0001593968-25-000414 · primary_01.xml · derivative · entry 2

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,603 shares

Expires not disclosed

F2 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $15.71 to $12.45.

F3 · derivative.expiration_date: The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

SEC source: 0001593968-25-000414 · primary_01.xml · derivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,474 shares

Expires 2029-04-04

F1 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $16.96 to $12.45.

SEC source: 0001593968-25-000413 · primary_01.xml · derivative · entry 6

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,603

Underlying: Common Stock · 1,603 shares

Expires not disclosed

F2 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $15.71 to $12.45.

F3 · derivative.expiration_date: The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

SEC source: 0001593968-25-000413 · primary_01.xml · derivative · entry 5

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,474

Underlying: Common Stock · 1,474 shares

Expires 2029-04-04

F1 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $16.96 to $12.45.

SEC source: 0001593968-25-000413 · primary_01.xml · derivative · entry 4

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F4 · kind: The warrant was cancelled pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025.

F6 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

F6 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

SEC source: 0001593968-25-000413 · primary_01.xml · derivative · entry 3

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F4 · kind: The warrant was cancelled pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025.

F5 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

F5 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

SEC source: 0001593968-25-000413 · primary_01.xml · derivative · entry 2

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,603 shares

Expires not disclosed

F2 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $15.71 to $12.45.

F3 · derivative.expiration_date: The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

SEC source: 0001593968-25-000413 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,474 shares

Expires 2029-04-04

F1 · kind: The warrant was repriced pursuant to a Warrant Cancellation and Amendment Agreement effective March 24, 2025 to decrease the per share exercise price of the warrant from $16.96 to $12.45.

SEC source: 0001593968-25-000110 · primary_01.xml · derivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-01-17

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on February 1, 2025, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-25-000112 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-01-17

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on February 1, 2025, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-25-000111 · primary_01.xml · derivative · entry 1

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-01-17

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on February 1, 2025, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-25-000041 · primary_01.xml · nonDerivative · entry 2

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,982

F3 · price: The shares were sold to cover withholding taxes upon vesting of RSUs in transactions that were initiated by the Issuer on the reporting person's behalf. The price reported reflects the volume-weighted average price for the transactions.